PMH19 ESCITALOPRAM IN THE TREATMENT OF KLEPTOMANIA  by Aboujaoude, E et al.
269Abstracts
who initiated an episode of drug therapy between July 1994 and
December 31, 1999. Episodes were required to have a minimum
of 6 months of pre-treatment and 12 months of post-treatment
data. Episodes were then separated into three time periods: 
a “closed-access period” prior to October 1997, a “transition
period” covering the ﬁrst 6 months of open access, and an “open
access period” for episodes initiated after April 1, 1998. Multi-
variate regression models were used to estimate the impact of
open access on total health care costs and duration of therapy.
COX proportional hazard models were estimated for time to dis-
continuation. RESULTS: The number of patients re-starting drug
therapy or augmenting an existing therapy increased immedi-
ately with open access due to increased use of second-generation
medications. Episode initiation rates returned to pre-open access
levels within 6 months (transition period). Open access signiﬁ-
cantly reduced total costs primarily due to signiﬁcant savings in
nursing home care ($1700 and $1807 for re-starters and aug-
menters, respectively). However, drug persistence also declined
with open-access: 42 fewer days for re-starters and 33 fewer days
for augmenters. Augmenters and re-starters were 16% and 12%
more likely to discontinue therapy if their episodes were initiated
in the open access period. CONCLUSIONS: The decision to
include atypical antipsychotics by the Medi-Cal program
resulted in lower persistency of drug therapy and lower total
health care costs. Decision-makers and program administrators
must use caution in evaluating the impact of open access to new
antipsychotic medications on patient outcomes and costs.
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OBJECTIVES: Kleptomania involves stealing items that are not
needed or have limited value from shops, strangers and acquain-
tances. Its prevalence is estimated at 6 per 1000 U.S. adults.
Kleptomania appears to account for 5% of shoplifting. No con-
trolled trials of pharmacotherapy for kleptomania have been
published. We are conducting the ﬁrst controlled trial of a med-
ication for kleptomania. METHODS: We are enrolling adults
aged 20 and older with kleptomania of 1 year’s duration,
meeting DSM-IV criteria and marked by court referral or steal-
ing at least once per week. We exclude individuals with psychotic
disorders, alcohol or substance abuse, bipolar disorder or anti-
social personality disorder. Subjects receive open-label escitalo-
pram 10mg/day for 4 weeks and if not “much improved,” take
20mg/day for an additional 3 weeks. A “responder” is a patient
experiencing at least 50% decrease in the Y-BOCS-kleptomania
version (Y-BOCS-K) scale score and a CGI-I score of much or
very much improved. Responders are randomized double blind
to continue for four months on either escitalopram or placebo.
RESULTS: We have enrolled 13 patients of a planned 24. Eleven
completed the seven weeks of open-label escitalopram; two dis-
continued. The 11 completers include 9 women with a mean age
of 46 years. Nine are employed full-time, one unemployed and
one a student. Five are married, three single, three divorced. Ten
of the 11 received escitalopram 20mg/day. The completers’ mean
Y-BOCS-K score decreased from 23.1 (SD 5.1) to 8.6 (SD 7.8)
at end of week 7. On a 0–4 scale, the strength of urges to steal
decreased from a mean of 2.9 (SD 0.7) to 1.1 (SD 0.8). The mean
number of weekly urges to steal decreased from 3.0 (SD 0.6) to
1.6 (SD 1.1). Eight subjects were responders. Of these eight, four
relapsed during the 4-month double blind, placebo-controlled
phase, but the blind remains unbroken. CONCLUSIONS: Early
results suggest a therapeutic effect for escitalopram in treating
kleptomania.
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OBJECTIVE: To compare rehospitalization rates of individuals
with schizophrenia who had been treated and discharged on
olanzapine or quetiapine from acute care hospitals. METHODS:
Using Premier’s PerspectiveTM database—the largest U.S. hos-
pital drug utilization database, rehospitalization status was
examined for inpatients with schizophrenia (ICD9-CM: 295.xx)
that were successfully treated and discharged on olanzapine (N
= 7573) or quetiapine (N = 3368) between January 1999 and
September 2001. A successfully treated patient was one who
started treatment with olanzapine or quetiapine in hospital and
discharged on the same antipsychotic. Time to readmission up
to 33 months was analyzed by Kaplan-Meier models. Cox pro-
portional hazard models were used to derive the hazard ratio
(HR) for rehospitalization by adjusting potential confounding
factors. RESULTS: Overall rehospitalization rate in the study
population was 35.3%. After adjusting for potential confound-
ing factors, quetiapine therapy (average daily dose = 356.1mg)
was associated with 25% increased risk of rehospitalization
compared to olanzapine (average daily dose = 17.3mg) (HR =
1.25, 95% conﬁdence interval 1.17–1.34, p < 0.0001). Addi-
tionally, younger age, schizoaffective/paranoid diagnoses, higher
severity level, and urban hospital location were signiﬁcantly
associated with higher risk of readmission. CONCLUSIONS:
This study suggests that olanzapine-treated patients had lower
risk of rehospitalization than quetiapine-treated patients. More-
over, certain patient demographic/clinical factors and institution
characteristics also inﬂuenced hospital readmission.
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OBJECTIVE: Quetiapine’s relatively broad dosage guidelines
(150–750mg/day) may result in suboptimal dosing. This study
investigated the association between quetiapine dose levels and
efﬁcacy as reﬂected in mental health resource use by patients
with schizophrenia or bipolar disorder. METHODS: Patients
who initiated quetiapine monotherapy and were treated for at
least 4 months were identiﬁed in a large health plan database
(1999–2002). Use of mental health resources other than queti-
apine was measured by charges on all medical claims for mental
disorders (ICD-9-CM codes 290.xx–316.xx) and on all pre-
scription claims for other psychotropic medications. Each
patient’s ﬁrst quetiapine prescription was used to identify the
target daily dose, because subsequent adjustments may have rep-
resented an effect rather than a determinant of health resource
use, which was measured in months 2, 3, and 4 of treatment.
Regression models controlling for patient differences measured
associations between initial quetiapine dose and subsequent
mental health charges. A signiﬁcant negative association between
dose levels and mental health resource use may be an indicator
of suboptimal dosing. RESULTS: Patients with schizophrenia (N
